E-LIB Suche - Ergebnisse für: Forconi, F.

1

Robust Bruton's tyrosine kinase (BTK) degradation with NX‐5..:

Linton, K. ; Forconi, F. ; Lewis, D....
Hematological Oncology. 41 (2023) S2 - p. 573-574 , 2023

Link: https://doi.org/10.1002/..

2

FOXO1‐RICTOR AXIS INDUCES AKT PHOSPHORYLATION DURING CLL CE..:

Ondrisova, L. ; Seda, V. ; Hoferkova, E....
Hematological Oncology. 41 (2023) S2 - p. 54-56 , 2023

Link: https://doi.org/10.1002/..

3

Lymph node location and retention properties of DC‐SIGN eng..:

Chiodin, G. ; Tatterton, D. ; Zhang, Y....
Hematological Oncology. 41 (2023) S2 - p. 256-256 , 2023

Link: https://doi.org/10.1002/..

4

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS ..:

Hillmen, P. ; Pitchford, A. ; Bloor, A....
HemaSphere. 6 (2022) - p. 46-47 , 2022

Link: https://doi.org/10.1097/..

5

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACT..:

Owen, R. ; McCarthy, H. ; Rule, S....
HemaSphere. 6 (2022) - p. 1020-1021 , 2022

Link: https://doi.org/10.1097/..

6

P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BT..:

Linton, K. ; Collins, G. P. ; El-Sharkawi, D....
HemaSphere. 6 (2022) - p. 548-549 , 2022

Link: https://doi.org/10.1097/..

7

INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMP..:

Condoluci, A. ; Terzi di Bergamo, L. ; Langerbeins, P....
Hematological Oncology. 37 (2019) S2 - p. 81-82 , 2019

Link: https://doi.org/10.1002/..

8

Genomic disruption of the histone methyltransferase SETD2 i..:

Parker, H ; Rose-Zerilli, M J J ; Larrayoz, M...
Leukemia. 30 (2016) 11 - p. 2179-2186 , 2016

Link: https://doi.org/10.1038/..

9

IL-10 production by CLL cells is enhanced in the anergic IG..:

Drennan, S ; D'Avola, A ; Gao, Y...
Leukemia. 31 (2016) 8 - p. 1686-1694 , 2016

Link: https://doi.org/10.1038/..

10

PI3Kδ inhibition elicits anti-leukemic effects through Bim-..:

Carter, M J ; Cox, K L ; Blakemore, S J...
Leukemia. 31 (2016) 6 - p. 1423-1433 , 2016

Link: https://doi.org/10.1038/..

11

Phenotypic heterogeneity in IGHV-mutated CLL patients has p..:

Pepper, C ; Buggins, A G S ; Jones, C H...
Leukemia. 29 (2014) 3 - p. 744-747 , 2014

Link: https://doi.org/10.1038/..

12

2‐Chlorodeoxyadenosine in the treatment of relapsed/refract..:

Rondelli, D. ; Lauria, F. ; Zinzani, P. L....
European Journal of Haematology. 58 (1997) 1 - p. 46-50 , 1997

Link: https://doi.org/10.1111/..

13

Activity of venetoclax in patients with relapsed or refract..:

Kater, Arnon P ; Arslan, Önder ; Demirkan, Fatih...
The Lancet Oncology. 25 (2024) 4 - p. 463-473 , 2024

Link: https://doi.org/10.1016/..

14

Development of a distributed international patient data reg..:

Andritsos, Leslie A. ; Anghelina, Mirela ; Neal, Jasmine...
Leukemia & Lymphoma. 63 (2022) 13 - p. 3021-3031 , 2022

Link: https://doi.org/10.1080/..

15

Hairy cell leukemia and COVID-19 adaptation of treatment gu..:

Grever, Michael ; Andritsos, Leslie ; Banerji, Versha...
Leukemia. 35 (2021) 7 - p. 1864-1872 , 2021

Link: https://doi.org/10.1038/..